Ninety One SA PTY Ltd Sells 913 Shares of Stryker Co. (NYSE:SYK)

Ninety One SA PTY Ltd lessened its stake in shares of Stryker Co. (NYSE:SYK) by 37.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,549 shares of the medical technology company’s stock after selling 913 shares during the quarter. Ninety One SA PTY Ltd’s holdings in Stryker were worth $464,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Ninety One North America Inc. boosted its stake in shares of Stryker by 2.9% during the fourth quarter. Ninety One North America Inc. now owns 18,545 shares of the medical technology company’s stock valued at $5,553,000 after purchasing an additional 522 shares during the period. OLD Second National Bank of Aurora boosted its stake in shares of Stryker by 0.9% during the fourth quarter. OLD Second National Bank of Aurora now owns 8,188 shares of the medical technology company’s stock valued at $2,452,000 after purchasing an additional 75 shares during the period. Peterson Wealth Services boosted its stake in shares of Stryker by 2.2% during the fourth quarter. Peterson Wealth Services now owns 12,098 shares of the medical technology company’s stock valued at $3,623,000 after purchasing an additional 255 shares during the period. Livforsakringsbolaget Skandia Omsesidigt boosted its stake in shares of Stryker by 3.0% during the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 10,979 shares of the medical technology company’s stock valued at $3,295,000 after purchasing an additional 322 shares during the period. Finally, Daiwa Securities Group Inc. lifted its stake in Stryker by 7.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 34,107 shares of the medical technology company’s stock worth $10,214,000 after acquiring an additional 2,468 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Transactions at Stryker

In other news, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Stryker news, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the transaction, the director now owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The disclosure for this sale can be found here. Insiders sold a total of 212,109 shares of company stock valued at $72,845,768 in the last quarter. 5.90% of the stock is owned by insiders.

Stryker Stock Down 2.6 %

Shares of SYK traded down $8.77 during trading hours on Thursday, hitting $327.26. The company had a trading volume of 1,193,477 shares, compared to its average volume of 1,250,812. The firm has a fifty day moving average price of $350.57 and a 200-day moving average price of $312.03. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58. The stock has a market capitalization of $124.51 billion, a price-to-earnings ratio of 39.89, a P/E/G ratio of 2.72 and a beta of 0.89. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.27 by $0.19. The firm had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. Stryker’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.00 EPS. On average, equities research analysts forecast that Stryker Co. will post 11.86 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 0.98%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio is presently 38.79%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and set a $360.00 price target for the company in a research note on Wednesday, January 31st. Truist Financial raised their price target on Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a research note on Wednesday, January 31st. Royal Bank of Canada raised their price target on Stryker from $360.00 to $386.00 and gave the stock an “outperform” rating in a research note on Monday. Roth Mkm raised their price target on Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Finally, Evercore ISI raised their price target on Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $340.45.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.